<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115958</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-001</org_study_id>
    <secondary_id>201401</secondary_id>
    <nct_id>NCT02115958</nct_id>
  </id_info>
  <brief_title>The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine</brief_title>
  <official_title>Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic of the Nasopharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors&#xD;
      into immunosuppressed mice, preventing an assessment on the immunologic interactions and&#xD;
      effects of CSCs. In this study, the investigators examined the vaccination effects produced&#xD;
      by CSC-enriched populations from histologically distinct murine tumors after their&#xD;
      inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic&#xD;
      and more effective as an antigen source than unselected tumor cells in inducing protective&#xD;
      antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which&#xD;
      bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from&#xD;
      peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were&#xD;
      capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed&#xD;
      antibodies and T cells were capable of selective targeting CSCs and conferring antitumor&#xD;
      immunity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the&#xD;
      investigators will harvest peripheral blood and tumor specimen from patients with&#xD;
      Nasopharyngeal Cancer. The investigators will purify T, B cells and generate DCs from the&#xD;
      PBMCs of the nasopharyngeal cancer patient.On the other hand, investigators will isolate&#xD;
      ALDHhigh and ALDHlow tumor cells from the tumor specimen of the nasopharyngeal cancer patient&#xD;
      using a similar protocol as investigators reported .&#xD;
&#xD;
      Aim 1: To demonstrate, in vitro, the relative cellular anti-nasopharyngeal cancer CSC&#xD;
      immunity induced by nasopharyngeal cancer CSC-DC primed cytotoxic T cells.&#xD;
&#xD;
      Aim 2: To determine, in vitro, specific binding and lysis of nasopharyngeal cancer CSCs by&#xD;
      antibodies produced by purified B cells from PBMCs stimulated with nasopharyngeal cancer&#xD;
      CSC-DC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The dose of CSC vaccine</measure>
    <time_frame>up to 3 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Neoplasms, Lung</condition>
  <arm_group>
    <arm_group_label>non-cancer stem cell vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>giving low dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>giving middle dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>giving high dose vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cancer stem cell vaccine</intervention_name>
    <arm_group_label>giving high dose vaccine</arm_group_label>
    <arm_group_label>giving low dose vaccine</arm_group_label>
    <arm_group_label>giving middle dose vaccine</arm_group_label>
    <arm_group_label>non-cancer stem cell vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.patients are greater than 18 years of age, with advanced local disease&#xD;
             (T3-T4N0-1M0), nodal disease (T1-T2N2-3M0) and loco-regional disease (T3-T4N2-3M0) at&#xD;
             onset but presently controlled by standard therapy (combination of chemotherapy and&#xD;
             radiotherapy) or with completely resected metastatic disease.&#xD;
&#xD;
             2.Pathologic confirmation of nasopharyngeal carcinoma by the NCI Laboratory of&#xD;
             Pathology (NPC).&#xD;
&#xD;
             3.serum creatinine of 2.0 mg/dl or less. 4.Total bilirubin 1.6 mg/dl or less, except&#xD;
             for patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0&#xD;
             mg/dl.&#xD;
&#xD;
             5.WBC 3000/mm(3) or greater. 6.platelet count 90,000 mm(3) or greater. 7.serum AST/ALT&#xD;
             less than three times normal. 8.ECOG performance status of 0 or 1. 9.Patients of both&#xD;
             genders must be willing to practice effective birth control during this trial because&#xD;
             the potential for teratogenic effects are unknown.&#xD;
&#xD;
             10.Patients may have had prior adjuvant treatment or may have had treatment for&#xD;
             metastatic disease and are now with no evidence of disease, including chemotherapy or&#xD;
             biotherapy, as long as 1 month has elapsed since prior systemic therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV. 2. level 3&#xD;
        hypertension; 3. severe coronary disease; 4. myelosuppression; 5. respiratory disease; 6.&#xD;
        brain metastasis; 7. chronic infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biological treatment center in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.fudahospital.com/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, Prince ME, Xu Y, Zhang XL, Huang S, Chang AE, Li Q. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012 Apr 1;72(7):1853-64. doi: 10.1158/0008-5472.CAN-11-1400.</citation>
    <PMID>22473314</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

